AR032422A1 - Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca - Google Patents

Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Info

Publication number
AR032422A1
AR032422A1 ARP020100315A ARP020100315A AR032422A1 AR 032422 A1 AR032422 A1 AR 032422A1 AR P020100315 A ARP020100315 A AR P020100315A AR P020100315 A ARP020100315 A AR P020100315A AR 032422 A1 AR032422 A1 AR 032422A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
inhibitors
cardiac disease
heart disease
Prior art date
Application number
ARP020100315A
Other languages
English (en)
Spanish (es)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR032422A1 publication Critical patent/AR032422A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP020100315A 2001-01-29 2002-01-29 Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca AR032422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (1)

Publication Number Publication Date
AR032422A1 true AR032422A1 (es) 2003-11-05

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100315A AR032422A1 (es) 2001-01-29 2002-01-29 Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Country Status (31)

Country Link
US (1) US20040234523A1 (cg-RX-API-DMAC10.html)
EP (1) EP1355668B1 (cg-RX-API-DMAC10.html)
JP (2) JP4860897B2 (cg-RX-API-DMAC10.html)
KR (1) KR100857376B1 (cg-RX-API-DMAC10.html)
CN (1) CN1326562C (cg-RX-API-DMAC10.html)
AR (1) AR032422A1 (cg-RX-API-DMAC10.html)
AT (1) ATE380558T1 (cg-RX-API-DMAC10.html)
BG (1) BG66483B1 (cg-RX-API-DMAC10.html)
BR (1) BR0206819A (cg-RX-API-DMAC10.html)
CA (1) CA2435466C (cg-RX-API-DMAC10.html)
CY (1) CY1107203T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ305653B6 (cg-RX-API-DMAC10.html)
DE (1) DE60224004T2 (cg-RX-API-DMAC10.html)
DK (1) DK1355668T3 (cg-RX-API-DMAC10.html)
EA (2) EA006767B1 (cg-RX-API-DMAC10.html)
EE (1) EE05534B1 (cg-RX-API-DMAC10.html)
ES (1) ES2295332T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20030609A2 (cg-RX-API-DMAC10.html)
HU (1) HU229164B1 (cg-RX-API-DMAC10.html)
IL (2) IL157024A0 (cg-RX-API-DMAC10.html)
ME (1) ME00549B (cg-RX-API-DMAC10.html)
MX (1) MXPA03006776A (cg-RX-API-DMAC10.html)
NO (1) NO331083B1 (cg-RX-API-DMAC10.html)
PL (1) PL213568B1 (cg-RX-API-DMAC10.html)
PT (1) PT1355668E (cg-RX-API-DMAC10.html)
RS (1) RS51125B (cg-RX-API-DMAC10.html)
SI (1) SI1355668T1 (cg-RX-API-DMAC10.html)
SK (1) SK287620B6 (cg-RX-API-DMAC10.html)
UA (1) UA80676C2 (cg-RX-API-DMAC10.html)
WO (1) WO2002060479A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200305439B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
AU2004238524B2 (en) 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン18阻害剤を有効成分とする疾患の予防又は治療剤
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
TW200927060A (en) 2007-11-05 2009-07-01 Kci Licensing Inc Identification of tissue for debridement
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
JP4094066B2 (ja) * 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−1β変換酵素のインヒビター
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165490B1 (en) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CA2369619A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
CA2407895C (en) * 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CN1326562C (zh) 2007-07-18
JP2009102354A (ja) 2009-05-14
YU57803A (sh) 2006-05-25
DE60224004T2 (de) 2009-07-23
PT1355668E (pt) 2008-01-04
NO331083B1 (no) 2011-10-03
EE05534B1 (et) 2012-04-16
DE60224004D1 (de) 2008-01-24
EA200501549A1 (ru) 2006-04-28
JP4860897B2 (ja) 2012-01-25
ZA200305439B (en) 2004-07-15
EE200300328A (et) 2003-10-15
HUP0303306A3 (en) 2005-12-28
EA006767B1 (ru) 2006-04-28
EA010180B1 (ru) 2008-06-30
CZ305653B6 (cs) 2016-01-27
HK1062810A1 (en) 2004-11-26
WO2002060479A1 (en) 2002-08-08
IL157024A (en) 2014-02-27
PL366802A1 (en) 2005-02-07
ME00549B (me) 2011-10-10
BG108128A (bg) 2004-11-30
BG66483B1 (bg) 2015-03-31
JP2004522748A (ja) 2004-07-29
CN1499982A (zh) 2004-05-26
CA2435466A1 (en) 2002-08-08
BR0206819A (pt) 2004-02-03
NO20033228L (no) 2003-09-26
HRP20030609A2 (en) 2005-06-30
HU229164B1 (en) 2013-09-30
EA200300844A1 (ru) 2003-12-25
CY1107203T1 (el) 2012-11-21
EP1355668B1 (en) 2007-12-12
HUP0303306A2 (hu) 2004-01-28
PL213568B1 (pl) 2013-03-29
MXPA03006776A (es) 2003-10-24
ES2295332T3 (es) 2008-04-16
NO20033228D0 (no) 2003-07-16
EP1355668A1 (en) 2003-10-29
RS51125B (sr) 2010-10-31
UA80676C2 (en) 2007-10-25
ATE380558T1 (de) 2007-12-15
SK10892003A3 (sk) 2004-02-03
CA2435466C (en) 2012-04-03
DK1355668T3 (da) 2008-05-05
KR100857376B1 (ko) 2008-09-05
SI1355668T1 (sl) 2008-06-30
IL157024A0 (en) 2004-02-08
CZ20032335A3 (en) 2004-07-14
US20040234523A1 (en) 2004-11-25
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05

Similar Documents

Publication Publication Date Title
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
DK2230308T3 (da) Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
SE0101932D0 (sv) Pharmaceutical combinations
SE0302488D0 (sv) New combination
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
TW200507829A (en) New combination
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
AR041595A1 (es) Tratamiento terapeutico
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ATE306267T1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
PA8558501A1 (es) 1,3-diarilprop-2-en1-onas, composiciones que las contienen y su utilizacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure